Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 70c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Castle Biosciences Reports Second Quarter 2022 Results
August 8, 2022 4:05 PM EDT
Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million
Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021
Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021
Raising 2022 Revenue Guidance to $130135 million from $118123 million
Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended... More
